Recent News

• 09.01.2026 - Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
• 08.12.2025 - Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
• 08.07.2025 - Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System
• 07.22.2025 - Daxor’s Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions
• 05.14.2025 - Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
• 05.13.2025 - Daxor’s Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems
• 05.07.2025 - Florida Healthcare Leader Embraces DAXOR Blood Volume Analysis Technology
• 05.06.2025 - Three New Medical Centers Adopt Daxor’s Blood Volume Diagnostic Signaling Growing Clinical Acceptance
• 04.22.2025 - Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
• 04.17.2025 - Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025

Recent Filings

• 09.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.31.2026 - NPORT-P Monthly Portfolio Investments Report on Form N-PORT (Public)
• 08.31.2026 - N-CSR Certified Shareholder Report
• 08.31.2026 - N-PX Annual Report of proxy voting record of management investment companies
• 06.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.25.2026 - 4 Statement of changes in beneficial ownership of securities